Luteinizing hormone-releasing hormone peptide tethered nanoparticulate system for enhanced antitumoral efficacy of paclitaxel

Ghanghoria R 1 , Tekade RK 2 , Mishra AK 3 , Chuttani K 3 , Jain NK 1

Affiliations 

  • 1 Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Sagar 470003 MP, India
  • 2 The University of Texas Southwestern Medical Center, Advanced Imaging Research Centre, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
  • 3 Division of Cyclotron & Radiopharmaceutical Sciences, Molecular Imaging Research Center, Institute of Nuclear Medicine & Allied Sciences (INMAS), DRDO, 110054 Delhi, India
Nanomedicine (Lond), 2016 Apr;11(7):797-816.
PMID: 26980704 DOI: 10.2217/nnm.16.19

Abstract

Paclitaxel (PTX) is an effective anticancer agent used in the therapy of a wide variety of cancers. However, the drug is difficult to formulate due to its low solubility, and therefore, it is administered under slow infusion with castor oil/ethanol solution as surfactant that causes serious side effects. This investigation investigates leutinizing hormone releasing hormone (LHRH)-tethered nanparticulate system as modality for cancer-specific delivery of PTX and therefore minimizing the adverse effects.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications